Chinese researchers tested stellar aberration navigation aboard the Tianhui-7 satellite in January, fixing its position to within 5km ahead of a 2030 Jupit
China's Ministry of Culture and Tourism issued a 15th Five-Year Plan for public cultural services, setting 2030 targets and 18 key engineering projects.
Friedrich Merz's CDU received just 5% in Mecklenburg-Vorpommern on Sunday, its worst state result since WWII, but the German chancellor vowed to press on.
Iran's security chief says Tehran has sent Washington conditions to end the war through Qatar, including lifting the US naval blockade, as oil crosses $100
UK filings show that Hong Kong’s Quri Investment Limited was listed as holding at least 75% of VSMPO Tirus Limited’s shares on 1 October 2026, the same day Russian titanium producer VSMPO-AVISMA ceased to be listed as having significant control. The filings do not disclose the terms of the deal.
Ed Sheeran opened his Philadelphia concert Saturday calling the Gaza situation 'catastrophic and unjustifiable' in his most direct public comment amid tour
All four supporting acts withdrew from Ed Sheeran's Loop tour on Monday in solidarity with rapper Macklemore, who was removed after pro-Palestine comments.
Thai elephant parks, including Maetaeng Elephant Park & Clinic, are facing a significant decline in tourist numbers due to global travel disruptions and uncertainty stemming from the Middle East conflict.
Players wore black armbands and fans applauded three-year-old Noah Woods during Everton's match against Ipswich on Saturday, after the boy's death in Suffo
Armand Duplantis and Jakob Ingebrigtsen each won $150,000 on the opening night of the first World Athletics Ultimate Championship in Budapest on Friday.
UK filings show that Hong Kong’s Quri Investment Limited was listed as holding at least 75% of VSMPO Tirus Limited’s shares on 1 October 2026, the same day Russian titanium producer VSMPO-AVISMA ceased to be listed as having significant control. The filings do not disclose the terms of the deal.
Novartis shares fell 9% on Tuesday after three drug trial setbacks, including its del-desiran and cholesterol programs, raising pressure on its pipeline.
Eli Lilly has sued six companies for allegedly selling versions of retatrutide, an experimental obesity drug still under clinical development and unapprove
CVS Health topped earnings estimates and raised its annual profit forecast on stronger drug revenues, unveiling a new Eli Lilly collaboration for Zepbound
Eli Lilly lifted its full-year revenue forecast as surging Mounjaro and Zepbound sales widened its lead over Novo Nordisk in the weight-loss drug market.